KPIs & Operating Metrics(New)

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Moderna (MRNA) Other financing activities (2018 - 2019)

Moderna (MRNA) has disclosed Other financing activities for 2 consecutive years, with -$3.7 million as the latest value for Q4 2019.

For Q4 2019, Other financing activities fell 137.2% year-over-year to -$3.7 million; the TTM value through Sep 2019 reached $13.6 million, changed N/A, while the annual FY2025 figure was $22.0 million, N/A changed from the prior year.
Other financing activities hit -$3.7 million in Q4 2019 for Moderna, down from $3.7 million in the prior quarter.
Across five years, Other financing activities topped out at $9.9 million in Q4 2018 and bottomed at -$3.7 million in Q4 2019.